Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells.
Zidovudine (AZT) treatment suppresses granulocyte-monocyte colony stimulating factor receptor type alpha (GM-CSFR alpha) gene expression in murine bone marrow cells.
复制标题
Zidovudine (AZT) 治疗可抑制小鼠骨髓细胞中粒细胞-单核细胞集落刺激因子受体 α 型 (GM-CSFR α) 基因表达。
DOI：
10.1016/s0024-3205(02)01790-3
复制
发表时间：
2002
期刊：
影响因子：
6.1
通讯作者：
Agrawal,KrishnaC
中科院分区：
文献类型：
--
作者：
Chitnis,Shilpa;Mondal,Debasis;Agrawal,KrishnaC
In vitro exposure of murine bone marrow cells to increasing concentrations of zidovudine (AZT, 0.1–50 μM) had a concentration dependent suppressive effect on the growth of granulocyte-monocyte colony forming unit (CFU-GM) derived colonies. In our previous published study, the mechanism of AZT-induced suppression of erythroid colony forming unit (CFU-E) derived colonies was linked to a decrease in erythropoitin receptor (Epo-R) gene expression. In this study, we have observed that AZT exposure also induced a concentration dependent suppressive effect (35–90%) on GM-CSF receptor type alpha (GM-CSFRα) gene expression. The suppression of GM-CSFRα mRNA expression was specific, since AZT caused a much lower decrease (15–22%) on the IL-3 receptor type alpha (IL-3Rα) message level, and had an insignificant effect on glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and c-myc message levels. Erythropoietin (Epo) therapy has been used for reversal of AZT induced erythroid toxicity. Exposure to increasing concentrations (10–500 U/ml) of GM-CSF was unable to override the suppressive effect of AZT on CFU-GM derived colonies, however, treatment in combination with IL-3 (10–250 U/ml) ameliorated the suppressive effects of AZT on CFU-GM and on GM-CSFRα and IL-3Rα gene expression. These findings suggest a mechanism via which AZT may suppress granulocyte-monocyte specific differentiation in murine bone marrow cells. These data also suggest that a combination of GM-CSF and IL-3 may be a superior therapeutic intervention for AZT-induced neutropenia.
